Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).
The registration certificate provides market-access authorization for the product in Guyana, subject to applicable local requirements. It does not by itself indicate that commercial sales or material overseas revenue have begun.
Conbercept is an anti-VEGF ophthalmic biologic developed by Kanghong for retinal diseases. The company did not disclose financial terms, an initial sales timetable or the scope of Guyana revenue expected from the authorization. Any reference to the locally approved indications should follow the wording on Guyana’s registration certificate, rather than assume that all indications approved in China apply in the new market.
The approval adds to Kanghong’s overseas registration footprint for Lumitin. The company has previously reported commercial exports of the product to several overseas markets, including Macao, Mongolia, Myanmar and Pakistan, while continuing to pursue registrations in other countries and regions.
Guyana is a relatively small market, so the immediate financial effect is likely to be limited. Its significance lies more in adding another regulatory authorization for a Chinese-developed biologic and providing experience in overseas registration, distribution and post-marketing compliance.
For Chinese innovative-drug companies, smaller overseas markets can offer a practical route to build international commercial capabilities. However, market authorization should be distinguished from product launch, sales conversion and sustained overseas revenue growth, all of which depend on local distribution, reimbursement, physician adoption and supply-chain execution.